Ongoing Clinical Trials for Noninfective Chorioretinitis
Currently, there is 1 ongoing clinical trial investigating treatment options for noninfective chorioretinitis, a condition involving inflammation inside the eye that is not caused by infection. This trial is testing brepocitinib, an oral medication, across multiple European countries. Patients with intermediate uveitis, posterior uveitis, or panuveitis may be eligible to participate in this research study aimed at reducing eye inflammation and improving symptoms.
Clinical trial locations
- Austria
- Belgium
- Czechia
- Germany
- Greece
- Hungary
- Italy
- Poland
- Spain
Study on the Effects of Brepocitinib and Prednisone for Adults with Active Non-Infectious Uveitis
This trial is investigating brepocitinib, an oral medication, combined with prednisone for treating active non-infectious uveitis. The study focuses on three specific types of uveitis: intermediate uveitis, posterior uveitis, and panuveitis. All of these involve inflammation in different parts of the eye that can lead to vision problems if not properly managed.
Who can participate:
- Adults aged 18 to 75 years
- People diagnosed with non-infectious uveitis, including intermediate, posterior, or panuveitis types
- Those with active inflammation currently present in at least one eye
- Individuals weighing more than 40 kilograms with a body mass index of 40 or less
Who cannot participate:
- Patients with other eye conditions that might interfere with study results
- Those who have recently had eye surgery or plan to undergo eye surgery during the study period
- People currently taking medications that could affect study outcomes
- Individuals with a history of severe allergic reactions to medications
- Patients with serious health conditions that could interfere with the study
- Pregnant or breastfeeding women
- Those already participating in another clinical trial
- Individuals with a history of drug or alcohol abuse
- People unable to follow study procedures or attend regular visits
What the trial involves: The study tests brepocitinib, a Janus kinase (JAK) inhibitor that works by blocking specific enzymes involved in the body’s inflammatory response. Participants will be randomly assigned to receive either brepocitinib or a placebo tablet that looks identical but contains no active medication. The study also involves the use of prednisone, a steroid medication, in varying doses.
The trial will last up to 96 weeks, during which participants will take their assigned medication and attend regular check-ups. Doctors will monitor how well the treatment reduces inflammation and improves symptoms such as blurred vision, floaters, and eye pain. They will also track any changes in visual acuity and measure the central subfield thickness in each eye to assess improvements.
Key measurements include evaluating the time until treatment failure between weeks 6 and 48, and the proportion of participants who experience treatment failure between weeks 6 and 24. The study is expected to begin recruiting participants in February 2025 and conclude by February 2028.
Investigational drug: Brepocitinib is an oral medication being studied for its ability to reduce inflammation in the eye. As a JAK inhibitor, it targets specific pathways in the immune system that contribute to inflammation. This Phase 3 trial aims to determine whether brepocitinib can effectively treat the symptoms of non-infectious uveitis and provide a new treatment option for patients living with this chronic eye condition.
Summary
There is currently one clinical trial available for patients with noninfective chorioretinitis, specifically focusing on non-infectious uveitis affecting the middle and back parts of the eye. The trial is being conducted across nine European countries, including Spain, Poland, Italy, Hungary, Austria, Germany, Belgium, Czechia, and Greece, indicating a significant multinational effort to research this condition.
The trial centers on brepocitinib, a JAK inhibitor that represents a newer approach to managing eye inflammation by targeting specific immune system pathways. The study design includes a placebo comparison and involves the additional use of prednisone, a well-established anti-inflammatory medication. With a duration of up to 96 weeks, this is a substantial long-term study that will provide valuable information about both the effectiveness and safety of this treatment approach.
Patients interested in participating should note that the trial has specific requirements regarding age, weight, and disease activity, and excludes those with certain other health conditions or medications. The wide geographic distribution of trial sites across Europe may provide greater access for eligible patients seeking participation in this research.